25.84 USD
▼-0.33-1.26%
盘后 25.61 -0.89%
2026-11-19
市值
$3.16B
市盈率
—
EPS
-5.41
股息率
—
52 周区间
23.82 – 43.10
成交量
2.77M
Beta
0.75
目标价
95.32
52W 低 23.8252W 高 43.10
价格走势
公司简介
Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. Its lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD. The company develops VK5211, an orally available non-steroidal selective androgen receptor modulator that is in Phase II c...
关联新闻
- Viking Therapeutics (VKTX) Price Forecast: Bullish Reversal Targets $43.55
Viking Therapeutics is showing early signs of a bullish reversal, with improving momentum and key support potentially setting up a recovery toward a major consolidation breakout.